Fundraising FoxTachyon Ventures — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsSofinnova VenturesvenBio PartnersMRL Ventures FundCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture Partners+8 more
EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Anthony DePasqua(Executive Officer, Director)inKevin Kalish(COO)inMarcie Glicksman(VP Biology)inWilliam Gormley(CMO)Jason Camm(Director)Kasper Roet(Director)in
Co-investors20/20 HealthCare Partners LLCDolby Family VenturesFlucas VenturesVU Venture PartnersAmgen VenturesBioverge+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.